Today, Explained Ecstasy Therapy: Bad trip
Aug 8, 2024
Sarah McNamee, a participant in a clinical trial for MDMA-assisted therapy, candidly shares her challenging experience, highlighting the gap between expectations and reality. She explores the emotional complexities of her journey with PTSD and the controversial aftermath of the therapy. The conversation raises critical questions about participant well-being, the ethical considerations of clinical trials, and the potential risks of MDMA therapy, revealing a nuanced perspective on mental health recovery amid the excitement over psychedelic treatments.
AI Snips
Chapters
Transcript
Episode notes
Sarah's Story
- Sarah McNamee, a trauma researcher, enrolled in an MDMA clinical trial for PTSD.
- She had prior trauma and used cooking as a coping mechanism.
First MDMA Session
- Sarah's first MDMA session had mixed results, starting with anxiety, moving to peacefulness, then intense trauma reliving.
- She felt a loss of control during the session.
Second MDMA Session
- Despite expressing concerns, Sarah was encouraged to take a higher dose of MDMA in her second session.
- This led to a worse experience with intense physical and emotional pain.